Sugi Predict

Sugi Predict / Compounds / SCHEMBL5125095

SCHEMBL5125095

SCHEMBL5125095

O=c1c2cc(O)ccc2[nH]c2c([N+](=O)[O-])ccc(Cl)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ HSP90AA1 P07900 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ CHEK1 O14757 7/20 0.43
▸ WEE1 P30291 6/20 0.43
▸ ROCK2 O75116 3/20 0.43
▸ POLB P06746 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ CASP6 P55212 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ FBP1 P09467 1/20 0.42
▸ CDK5 Q00535 3/20 0.40
▸ CDK5R1 Q15078 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10642510 0.90 GLI1 (0.43) MEN1KMT2ANPC1ALDH1A1LMNA
SCHEMBL7058105 0.85 ALDH1A1 (0.45) MEN1KMT2ANPC1ALDH1A1LMNA
SCHEMBL7064339 0.85 ALDH1A1 (0.45) MEN1KMT2ANPC1ALDH1A1LMNA
SCHEMBL10651679 0.85 MEN1 (0.48) MEN1KMT2ANPC1ALDH1A1LMNA
SCHEMBL7062949 0.82 LMNA (0.43) MEN1KMT2ANPC1ALDH1A1LMNA
SCHEMBL3376659 0.82 CTSV (0.56) MEN1KMT2ANPC1ALDH1A1LMNA
SCHEMBL7059598 0.82 VCAM1 (0.52) MEN1KMT2ANPC1ALDH1A1LMNA
SCHEMBL8807470 0.82 LMNA (0.43) MEN1KMT2ANPC1ALDH1A1LMNA
SCHEMBL10645311 0.82 MAPT (0.44) MEN1KMT2ANPC1ALDH1A1LMNA
SCHEMBL7220724 0.82 SIRT2 (0.46) MEN1KMT2ANPC1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202349-B2 Asymmetric bis-acridines with antitumour activity and their uses Gdansk University of Technology (PL) 2019-02-12 — — US disclosed
US-20180086712-A1 ASYMMETRIC BIS-ACRIDINES WITH ANTITUMOUR ACTIVITY AND THEIR USES Gdansk University of Technology (PL) 2018-03-29 — — US disclosed
EP-3070078-B1 ASYMMETRIC BIS-ACRIDINES WITH ANTITUMOR ACTIVITY AND USE THEREOF POLITECHNIKA GDANSKA (PL) 2017-10-04 — — EP disclosed
WO-2016150799-A1 ASYMMETRIC BIS-ACRIDINES WITH ANTITUMOUR ACTIVITY AND THEIR USES Politechnika Gdańska (PL) 2016-09-29 — — WO disclosed
EP-3070078-A1 Unsymetrical bisacridines with antitumor activity and use thereof Politechnika Gdanska (PL) 2016-09-21 — — EP disclosed
WO-2008016661-A2 MORPHOLINO COMPOUNDS FOR TREATING INFLAMMATORY AND DEMYELINATING DISEASES AND CANCERS XANTHUS PHARMACEUTICALS, INC. (US) 2008-02-07 — — WO disclosed
EP-0597956-A1 QUINAZOLINE DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1994-05-25 — — EP disclosed
EP-0579614-A1 IMIDAZOACRIDINES AND THEIR ANTINEOPLASTIC USE. BRITISH TECH GROUP (GB) 1994-01-26 — — EP disclosed
WO-1992015583-A1 IMIDAZOACRIDINES AND THEIR ANTINEOPLASTIC USE BRITISH TECHNOLOGY GROUP LTD. (GB) 1992-09-17 — — WO disclosed
EP-0502668-A1 Imidazoacridines and their antineoplastic use BTG INTERNATIONAL LIMITED (GB) 1992-09-09 — — EP disclosed
EP-0145226-B1 SUBSTITUTED 1-AMINO-4-NITRO-ACRIDINONES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND PROCESSES FOR THEIR PRODUCTION WARNER-LAMBERT COMPANY (US) 1988-10-05 — — EP disclosed
EP-0138302-B1 PYRAZOLO(3,4,5-KL)ACRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND PROCESSES FOR THEIR PRODUCTION WARNER-LAMBERT COMPANY (US) 1988-03-09 — — EP disclosed
US-4626540-A Substituted 1-amino-4-nitro-acridinones and methods of treating bacterial infections and leukemia with them WARNER-LAMBERT COMPANY (US) 1986-12-02 — — US disclosed
US-4621086-A Method of treating leukemia with pyrazolo[3,4,5-kl]acridines WARNER-LAMBERT COMPANY (US) 1986-11-04 — — US disclosed
US-4588730-A Pyrazolo[3,4,5-k1]acridine compositions and methods for their use as antimicrobials WARNER-LAMBERT COMPANY (US) 1986-05-13 — — US disclosed
US-4555572-A Pyrazolo[3,4,5-kl]acridine compositions and methods for their production and use WARNER-LAMBERT COMPANY (US) 1985-11-26 — — US disclosed
EP-0145226-A2 Substituted 1-amino-4-nitro-acridinones, pharmaceutical compositions comprising the same and processes for their production WARNER-LAMBERT COMPANY (US) 1985-06-19 — — EP disclosed
EP-0138302-A1 Pyrazolo(3,4,5-kl)acridine compounds, pharmaceutical compositions comprising the same and processes for their production WARNER-LAMBERT COMPANY (US) 1985-04-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202349-B2 Asymmetric bis-acridines with antitumour activity and their uses MCL1, BAD, ACR MEN1 1879/4885KMT2A 3317/4885NPC1 1931/4885
US-20180086712-A1 ASYMMETRIC BIS-ACRIDINES WITH ANTITUMOUR ACTIVITY AND THEIR USES MCL1, ACR, BAD MEN1 1739/4885KMT2A 3143/4885NPC1 1954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.